All In Biotech

Drug Trial Radar · NCT00004978

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy

A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial

Last checked: Nov 19, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,150

Actual

Start

Mar 2000

Primary completion

Nov 2008

Study completion Nov 2008

Sponsor

Sponsor type
NIH
Collaborators
Chiron Corporation
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease progression. Anti-HIV therapy has been very successful in treating HIV positive patients and in keeping viral load (level of HIV in the blood) low. However, anti-HIV drugs cannot completely rid the body of the virus, and the immune system is never completely restored in HIV positive patients. Doctors hope that giving patients recombinant interleukin-2 (rIL-2) in addition to their anti-HIV therapy will help improve their immune systems and keep them healthier over a longer period of time. rIL-2 is a hormone naturally produced by the body during an immune response to a microbial infection.

Conditions

  • HIV Infections

Interventions

  • Recombinant interleukin-2 (rIL-2)Drug

    Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. New or Recurrent HIV Disease Progression Event Including DeathTime frame: from randomization through study end - median of 7.6 years follow-up

Locations

248 sites in 25 countries. Site status is shown where the registry gives one.

  • VA Greater Los Angeles Healthcare System, Infectious Diseases Section CRS

    Los Angeles, California

  • Dr. M. Estes Med. Practice CRS

    Mill Valley, California

  • Dr. Robert Scott Med. Practice CRS

    Oakland, California

  • East Bay AIDS Ctr. CRS

    Oakland, California

  • Dr. Shawn Hassler Med. Practice CRS

    San Francisco, California

  • Positive Health Program Clinic (San Francisco Gen. Hosp.) CRS

    San Francisco, California

  • Positive Health Practice West/ Dr. Steve Deeks CRS

    San Francisco, California

  • Dr. William Owen Med. Practice CRS

    San Francisco, California

  • Dr. Martin Mass Med. Practice CRS

    San Francisco, California

  • San Francisco VAMC, Infectious Diseases Clinic CRS

    San Francisco, California

  • UCSF PHP, Gen. Internal Medicine Practice CRS

    San Francisco, California

  • Castro-Mission Health Ctr. CRS

    San Francisco, California

  • Dr. Virginia Cafaro Med. Practice CRS

    San Francisco, California

  • Denver Infectious Diseases Consultants CRS

    Denver, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • Univ. of Colorado Health Science Ctr. CRS

    Denver, Colorado

  • Whitman-Walker Clinic CRS

    Washington D.C., District of Columbia

  • George Washington Univ. Med. Ctr. Infectious Diseases - Clinical Trials Unit CRS

    Washington D.C., District of Columbia

  • Walter Reed Army Med. Ctr., Infectious Disease Clinic CRS

    Washington D.C., District of Columbia

  • Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS

    Washington D.C., District of Columbia

  • Dr. Timothy A. Price Med. Practice CRS

    Washington D.C., District of Columbia

  • Miami VAMC CRS

    Miami, Florida

  • Univ. of Miami, Infectious Diseases Clinical Research Unit CRS

    Miami, Florida

  • ARCA, Central Clinc CRS

    Atlanta, Georgia

  • Emory Univ. Crawford Long Hosp. CRS

    Atlanta, Georgia

  • Atlanta VAMC CRS

    Decatur, Georgia

  • Klein & Slotten Medical Associates CRS

    Chicago, Illinois

  • Jesse Brown VAMC CRS

    Chicago, Illinois

  • Univ. of Illinois Family Ctr. for Infectious Disease CRS

    Chicago, Illinois

  • Lakeshore Infectious Disease Associates CRS

    Chicago, Illinois

  • North Side Family Medicine CRS

    Chicago, Illinois

  • Northwestern Memorial Physicians Group CRS

    Chicago, Illinois

  • Med. Ctr. of Louisiana at New Orleans, HIV Outpatient Clinics CRS

    New Orleans, Louisiana

  • Tulane University Health Sciences Center, Louisiana Community AIDS Research Program(LaCARP) CRS

    New Orleans, Louisiana

  • New Orleans VAMC CRS

    New Orleans, Louisiana

  • NIH Clinical Ctr., NIAID HIV Clinic CRS

    Bethesda, Maryland

  • National Naval Med. Ctr., Infectious Diseases Special Immunology Clinic CRS

    Bethesda, Maryland

  • Henry Ford Hosp. CRS

    Detroit, Michigan

  • Wayne State Univ. CRS

    Detroit, Michigan

  • St. John Hosp. & Med. Ctr., Infectious Diseases Dept. CRS

    Grosse Pointe Woods, Michigan

Showing 40 of 248 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.